RecruitingNCT07188077

Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma

Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma Based on Metabolomics and Immunomics

Sponsor

Ting YANG

Enrollment

20 participants

Start Date

Mar 1, 2025

Study Type

OBSERVATIONAL

Conditions

Primary Central Nervous System Lymphoma (PCNSL)

Summary

This study is a prospective cohort study. The case group will include patients with primary central nervous system lymphoma confirmed by imaging and pathology. The control group will include patients with pathologically confirmed diffuse large B-cell lymphoma who have been excluded from central nervous system involvement, as well as age- and gender-matched healthy volunteers (hematopoietic stem cell donors). Baseline data (as described below) will be collected. Patients with primary CNS lymphoma will undergo follow-up every 3 months, with immediate follow-up if clinical symptoms arise.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at differences in metabolism and immune system activity between patients with a type of brain lymphoma (a cancer of the immune cells in the brain) and healthy people. The goal is to better understand how this rare cancer behaves at the molecular level. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with primary central nervous system lymphoma (a lymphoma that started in the brain or spinal cord) and have not yet received any cancer treatment - Or you are a healthy volunteer with no major illnesses **You may NOT be eligible if...** - You have already started cancer treatment before the initial blood or tissue sample is taken - You have conditions that would make blood draws or other procedures unsafe - You do not meet health criteria set by the study team Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

The First Affiliated Hospital of Fujian Medical University

Fuzhou, Fujian, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07188077

Related Trials

Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

NCT075237371 location

A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

NCT070828688 locations

PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.

NCT074105201 location

A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants

NCT071980872 locations

Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL

NCT070744701 location